| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Bemiparin Sodium | Hibor | 4.3 Contraindications | Hypersensitivity to sodium bemiparin, heparin or its derivatives, including other low molecular weight heparins | Mar,2023 |
| Acetylsalicylic Acid | Aspirin® Protect | 4.8 Undesirable effects | Drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms | Mar,2023 |
| Atezolizumab | Tecentriq | 4.4 Special Warnings and Special Precautions for Use | Haemophagocytic lymphohistiocytosis and Gastrointestinal perforation | Mar,2023 |
| Lansoprazole | Takepron | 4.4 Special Warnings and Special Precautions for Use 4.8 Undesirable effects | Stevens-Johnson syndrome , toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms and acute generalized exanthematous pustulosis | Mar,2023 |
| Colistimethate Sodium | Colistin | 4.4 Special Warnings and Special Precautions for Use 4.8 Undesirable effects | Pseudo-Bartter syndrome | Mar,2023 |
| Bosutinib | Bosulif | 4.8 Undesirable effects | Interstitial lung disease | Mar,2023 |